India, Feb. 12 -- AbbVie Inc. (ABBV) announced on Monday that it has revised down its first-quarter earnings outlook, which came in below analysts' estimates. Further, the company reaffirmed annual income per share guidance in line with the Street view.
In addition, AbbVie has announced the closing of its previously announced acquisition of ImmunoGen (IMGN). Excluding items, for the first quarter, the drug maker now expects income per share of $2.26 to $2.30 against its previous expectation of $2.30 to $2.34 per share.
This guidance now reflects a $0.04 per share dilutive impact related to the ImmunoGen acquisition.
On average, 16 analysts polled by Thomson Reuters forecast the firm to earn income per share of $2.39, for the quarter. Ana...